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receiving cyclosporine/MMF (Nash et al, BBMT 2005), children have
signiﬁcantly higher MMF clearance rates (1.2 vs 0.54 L/kg/h). MMF
doses  3-fold higher than those used in pediatric SOT recipients
were required to achieve AUC0-630-60 mg  h/L. Short T1/2 and
rapid clearance of MMF in pediatric AlloSCT pts may be related to a
lack of enterohepatic recycling and enhanced UDP-glucuronosyl-
transferase activity.
Table 1. Age-related IV MMF PK on Day 14.
Age
Group
Cmax
(mg/L)
Tmax
(h)
Total
MPA
trough
(mg/L)
Mean
AUC0-6
(mg  h/L)
T1/2
(h)
Vss
(L/kg)
CL
(L/kg/h)
< 6
y.o.
(n8) 13.8 1.9 1.2 37.1 1.7 2.1 1.4
6-12
y.o.
(n8) 14.8 2.0 0.4 35.8 0.9 1.4 1.3
12-16
y.o.
(n7) 25.2 1.6 1.1 45.8 1.3 1.2 0.8
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CHARACTERISTICS OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN
BRAZILIAN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS: A
FIVE-YEAR RETROSPECTIVE ANALYSIS
Bouzas, L.F.S.1, Moreira, M.C.P.1, Tavares, R.d.C.B.1, Lerner, D.1,
Azevedo, A.M.1, Mattos, M.1, Horn, P.1, Collares, M.1, Mellin, S.1
1Instituto Nacional do Cancer, Rio de Janeiro, Brazil.
Chronic graft-versus-host disease (cGVHD) is the leading cause
of non-relapse morbidity and mortality in the post-transplantation
period. Incidence rates and clinical characteristics have been
changing considerably in recent years, following increases in the
use of new sources of stem cells and donor/recipient age and the
introduction of new modalities of conditioning regimens. Inci-
dence rates reported in the literature have ranged from 20 to 70%,
being lower in the pediatric population and in recipients of cord
blood grafts. Use of donor lymphocyte infusions as a strategy to
control minimal residual disease or treat relapse is also a risk factor
for cGVHD. Among 95 patients analyzed, 29 (30.5%) were fe-
males. Median age was 35 years (18-64). Eighty seven patients had
hematologic malignancies (91.5%). The conditioning regimen was
myeloablative in 79 (83%). Bone marrow was used in 74 (78%) and
peripheral blood in 21 (22%). Prophylaxis of GVHD was done
with cyclosporine and methotrexate in 88 (92.5%). Sixty six
(69.5%) patients had acute GVHD before cGVHD. The median
time for the ﬁrst manifestation of cGVHD was 132 days (33-1499).
The installation of cGVHD was progressive in 37 (49%). Extensive
disease was present in 42 (56%). Eosinophilia (500/ul) was found
in 12 (16.5%). Lymphopenia (500/ul) was present in 19 (25%).
Thrombocytopenia ( 100,000/ul) was seen in 32 (41.5%). The
ﬁndings in our series are in accordance with the clinical proﬁle
usually reported in the literature. Because of its high morbidity and
mortality, the need for early detection of cGVHD can not be
overstated. Systematic, prospective evaluation of patients at risk for
this complication can contribute to better understanding of the
disease, and possibly, better control of the complications and im-
pact of advanced cGVHD in quality of life and survival expectancy.
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PRE-TRANSPLANT BIOMARKERS PREDICT GVHD AND TREATMENT-
RELATED MORTALITY IN PATIENTS TREATED WITH EXTRACORPO-
REAL PHOTOPHERESIS PRIOR TO ALLOGENEIC BONE MARROW
TRANSPLANTATION
O’Brien, P.J.1, Bolwell, B.2, Abhyankar, S.3, Shaughnessy, P.4,
Williamson, P.1, Campbell, K.A.1 1Therakos Inc., Exton, PA; 2The
Cleveland Clinic Foundation Bone Marrow Transplant, Cleveland, OH;
3Kansas City Cancer Center, Kansas City, MO; 4Texas Transplant
Institute, San Antonio, TX; 5University of Chicago, Chicago, IL.
Accurate prediction of the onset and severity of GvHD and
treatment-related mortality (TRM) can improve outcomes
through optimized donor selection and GvHD prophylaxis. Cur-
rent assessments are typically made after bone marrow transplan-
tation (BMT), and often require inherently unreliable qualitative
measures. The persistence of host antigen presenting cells, partic-
ularly dendritic cells (DC) has been implicated in the onset of
GvHD, and a recent data suggests that extracorporeal photophere-
sis (ECP) can prevent GvHD after allogeneic BMT. We examined
blood from 32 ECP-treated patients to identify cell surface mark-
ers that might predict GvHD and TRM. Samples were drawn
immediately prior to ECP (at baseline) and immediately after ECP,
but prior to myeloablative conditioning, then assayed by ﬂow
cytometry. Cytometry data were grouped and modeled to assess
their predictive accuracy alone or in combination with clinical
laboratory values. Logistic regression showed that speciﬁc DC
subsets present prior to myeloablation were the best predictors of
outcomes. The likelihood of grade II-IV GvHD (aGvHD) in-
creases when baseline lin- HLA-DR CD11c myeloid cells make
up a smaller proportion of circulating mononuclear cells with a
predictive accuracy, reﬂected in the area under the receiver-oper-
ator curve (ROC) of 0.83. The best predictive model for TRM was
a lower absolute abundance of circulating lin- HLA-DR CD123
plasmacytoid DC at baseline (ROC0.86). No additional predic-
tive power arose with respect to aGvHD or TRM after including
laboratory values. Models that combined certain clinical laboratory
results and demographic factors also predicted these clinical out-
comes, and offer a possible alternative to complex cytometric
assays. The best such model included baseline measurements of
BUN/Creatinine ratio, serum albumin, and the match/relatedness
of the graft donor and recipient (ROC0.82, n59) for TRM,
while baseline neutrophil counts were most predictive of aGvHD
(ROC0.69, n60).
In summary, we have identiﬁed biomarkers that, at least in
patients receiving ECP, are present before conditioning and can
predict outcomes. Although this study does not address the impact
of ECP on antigen presenting cells directly, the DC proﬁles de-
scribed here highlight the potential role of ECP in modulating
DC, and thereby decreasing the risks associated with BMT. These
results encourage larger studies with non-ECP control populations
to directly address this issue.
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EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR THE TREATMENT OF
STEROID-REFRACTORY OR -INTOLERANT CHRONIC GRAFT-VERSUS-
HOST DISEASE (CGVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT (HSCT)
Pawarode, A.1,2, Hahn, T.1, Battiwalla, M.1, McCarthy, P.L.1 1BMT
Section, Department of Medicine, Roswell Park Cancer Institute, Buf-
falo, NY; 2Division of Hematology, Department of Medicine, University
at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY.
We report our long-term results using extracorporeal photo-
pheresis (ECP) for the treatment of chronic graft-versus-host dis-
ease (cGvHD). Between 2002 and 2005, 21 patients with steroid-
refractory or -intolerant cGvHD received ECP for a median
duration of 10.8 (range 1.3-58.8) months (Table). HSCT types
were 14 HLA-matched related donor (MRD), 6 HLA-matched
unrelated donor (MUD) and 1 HLA-mismatched unrelated cord
blood donor. Standard GvHD prophylaxis included a calcineurin
inhibitor with methotrexate (18), or methylprednisolone (2) or
both (1). Two (9.5%), 11 (52.4%) and 8 (38.1%) cases had mild,
moderate and severe cGvHD by CIBMTR criteria. Among the 19
patients with adequate follow-up (6 months post ECP initiation),
the sustained overall and complete response (OR and CR) rates
were 84.2 % (16/19) and 42.1% (8/19) with the maximum response
occurring at the median time of 1.8 (0.6-3.5) months from ECP
initiation. OR and CR rates by CIBMTR severity grading were
50% and 50% in the mild group, 45.4% and 36.4% in moderate
group, and 62.5% and 37.5% in severe group. Steroid-sparing
(steroid discontinuation or requiring adrenal doses only) was
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achieved in 81.2% (13/16) of responders, and occurred a median 10
(2-34.7) months after ECP. Nine cases (56.2%) had recurrent
cGvHD at 8.4 (3-19.3) months after achieving response and 1
(6.25%) had late primary disease relapse (6 months after ECP
initiation). Another non-responder had a late relapse. Factors as-
sociated with OR were younger age at cGvHD diagnosis and at
ECP initiation (50 years, P0.046), while that with CR was early
initiation of ECP within 18 months of cGvHD diagnosis
(P0.018). The 1-year, 2-year and 3-year post ECP initiation
survival rates were 66.7%, 38.1% and 23.8%. Types of cGvHD
onset and donor were associated with survival post ECP initiation
(P0.028 and P0.05). The patients with non-progressive onset
cGvHD and with HLA-MRD survived longer (1-year post ECP
initiation survival rates of 88.9% and 78.6%) than those with
progressive onset cGvHD and with HLA-MUD (50% and 33.3%).
However, OR and CR to ECP were not associated with prolonged
post ECP initiation survival. In summary, our results suggest that
ECP is an effective second-line treatment option for cGvHD
especially with early initiation. Progressive onset cGvHD and
HLA-MUD were associated with poor survival rates in patients
receiving ECP for cGvHD. Whether response to ECP would be
translated to higher survival requires a larger study.
Table
Characteristics Details
Sex: male/female (n/n) 9/12
Median age (median, range)
-- At day 0 42.6 (26.5-60.1) years
-- At cGvHD diagnosis 42.8 (26.8-60.4) years
-- At ECP initiation 43.4 (28-60.4) years
Type: HLA-MRD/-MUD/-
mismatched unrelated CBD
(n) 14/6/1
GvHD Prophylaxis (n)
-- Calcineurin inhibitor and
methotrexate 18
-- Calcineurin inhibitor and
methylprednisolone 2
-- Triple regimen 1
Acute GvHD (n) 19
-- Clinical Grade: I/II/III/IV 5/12/1/1
-- ECP for aGvHD 1
Chronic GvHD (n) 21
-- Onset: De novo/Progressive/
Recurrent (n) 1/13/7
-- CIBMTR Overall
Severity at ECP
initiation (n)
........Mild 2
........Moderate 11
........Severe 8
-- Maximum Grade (n)
........Limited 3
........Extensive 18
-- Median duration of ECP
(median, range)
10.8 (1.3-58.8)
months
-- Median follow-up time
after ECP initiation
(median,range)
15.5 (1.3-62.4)
months
-- Overall and complete
response to ECP by
CIBMTR Severity
........Mild (n (%)) 1 (50%), 1 (50%)
........Moderate (n (%)) 5 (45.4%), 4 (36.4%)
........Severe (n (%)) 5 (62.5%), 3 (37.5%)
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INTERACTION BETWEEN HOST NATURAL KILLER T CELLS AND DONOR
CD4CD25 TREG CELLS PROTECTS AGAINST GVHD AFTER TLI/ATS
HOST CONDITIONING AND ALLOGENEIC BONE MARROW TRANSPLAN-
TATION
Pillai, A.B.1, Dutt, S.1, George, T.I.1, Strober, S.A.1 1Stanford Uni-
versity School of Medicine, Stanford, CA.
The murine non-myeloablative regimen of total lymphoid irra-
diation (TLI) and anti-thymocyte serum (ATS) prevents acute
graft-versus host disease (aGVHD) and was recently successfully
applied for human hematolymphoid malignancies (Lowsky et al,
NEJM, 2005). To investigate GVHD protection, we transplanted
(BMT) 50 106 bone marrow cells and 60 106 splenocytes from
wild-type (WT), CD4-/-, IL-4-/-, or IL-10-/- C57BL/6 (H-2b) do-
nor mice into wild-type (WT) or natural killer (NK) T cell deﬁ-
cient J
18-/- BALB/c (H-2d) hosts following TLI/ATS. Controls
were WT BALB/c mice given 800cGy total body irradiation (TBI)
and ATS with BMT from WT C57BL/6 donors. TBI/ATS-con-
ditioned WT hosts given BMT from WT donors and TLI/ATS
conditioned WT hosts given BMT from CD4-/-, IL-4-/-, or IL-
10-/- donors developed aGVHD, with marked donor CD8 T cell
accumulation in liver, mesenteric lymph nodes (MLN), and colon
at day 6. Since GVHD protection depends on donor CD4 cells,
IL-4, and IL-10, we investigated the role of donor CD4 Tregs in
GVHD protection. TLI/ATS-conditioned WT hosts given BMT
from WT donors survived without aGVHD and demonstrated a
dramatic (p 0.01) ten-fold increase in the absolute number of
donor CD4CD25Foxp3Tregs in the spleen at day 6 after BMT
relative to TBI/ATS-conditioned WT hosts or TLI/ATS-condi-
tioned J
18-/- hosts that succumbed to aGVHD. These
CD4CD25Foxp3 Tregs secreted IL-4 and IL-10 and had the
GVHD suppression capacity of conventional CD4CD25 Tregs.
Pre-transplant adoptive transfer of sorted WT host invariant NK
T cells protected TLI/ATS-conditioned J
18-/- hosts from day 6
donor CD8 T cell accumulation and caused a signiﬁcant
(p  0.01) increase in the absolute number of donor
CD4CD25Foxp3 Tregs. Using congenic markers (CD45.1/
CD45.2), we found that these CD4Tregs arise from donor splenic
(peripheral) T cells after BMT. CD25 depletion of WT donor cells
before BMT into TLI/ATS-conditioned WT hosts or into TLI/
ATS-conditioned J
18-/- hosts given adoptive transfer of WT host
NK T cells resulted in loss of the donor CD4CD25Foxp3
Tregs subsets in the spleen, and signiﬁcantly increased day 6 donor
CD8 T cell accumulation in the host liver, MLN, and colon,
accompanied by lethal aGVHD. These studies show that host
invariant NK T cells are critical for GVHD protection and that
they can facilitate the expansion of donor CD4CD25Foxp3
Tregs, which protect TLI/ATS treated hosts from lethal GVHD
after allogeneic BMT.
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IN VIVO ACTIVATION OF APCS WITH TLR LIGANDS AND TISSUE DAM-
AGE RATHER THAN AMOUNT OF HOST APCS ARE CRITICAL FACTORS
THAT DETERMINE DLI-MEDIATED GVL REACTIVITY AND GVHD IN
MHC-MATCHED MINOR HISTOCOMPATIBILITY ANTIGEN (MHAG)-MIS-
MATCHED CHIMERAS
Radojcic, V.1, Skarica, M.1, Murphy, G.F.2, Luznik, L.1 1Division of
Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Cen-
ter at Johns Hopkins, Baltimore, MD; 2Department of Pathology,
Brigham and Women’s Hospital and Harvard Medical School, Boston,
MA.
We recently found that residual host CD11c DCs persist in the
skin of MHC-matched chimeras after myeloablative conditioning
and transplantation of T cell-repleted BM, and that those residual
host APCs are insufﬁcient for the induction of optimal DLI-
mediated alloreactivity (J Immunol.,2006). Since the latter obser-
vation in established C3H.SW3B6 chimeras differs from the
current paradigm in freshly irradiated MHC-matched chimeras,
we hypothesized that in established chimeras, beside host APCs
and donor T cells, the induction of DLI-mediated GVL reactivity
and GVHD requires two additional factors: (a) TLR-mediated
activation of APCs and (b) tissue damage. In vivo coadministration
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